Antibe Therapeutics Inc(Pre-Merger) ATBPF

News Release

[Duster340]

ANTIBE THERAPEUTICS INC.
15 Prince Arthur Ave.
Toronto, ON, Canada, M5R 1B2
TSX:ATE OTCQX:ATBPF
antibethera.com

November 16, 2023
 

Hi everyone,

This is just a quick note to share a recent article in Barron's (a WSJ publication) that speaks eloquently to the market opportunity for novel non-opioids, including this statement:

"A nonaddictive pain pill that works as well as an opioid, with none of the same addiction risk and side effects, would be an instant blockbuster."

That's a good summary of otenaproxesul's target product profile, of course. You can find the article at barrons.com/articles/vertex-pain-pill-non-opioid-573cae68 -- unfortunately, it's paywalled but the first few paragraphs capture it nicely (including the quote above).

Best,

Christina

 p.s. Also hear Dan Legault, our CEO, in an interview yesterday that includes discussion of the Barron's article by clicking on the link here.


Contact Information
Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
[phone]
[e-mail]

[Harper75]

I received this email as well but I found it very odd Investor Relations would send out an article that is highlighting another Pharm's progress on their non-opioid pain pill even if it highlights the need and opportunity in the market.  Made me want to look closer at Vertex...

[WalkOverTheStrt]

Marcket cap of $90B and ~$350 a share... I think the attempt is to show potential of Antibe if they finally are sucessful and reach the finish line. I'd expect Antibe to hit the editorials/news cycle if PH2 is successful to drum up more eyes.